Company intelligence / Profile preview

LabGenius

London, United Kingdomlabgeni.us ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

LabGenius has demonstrated the ability to rapidly design and test tens of thousands of novel antibody candidates using its AI-driven EVA™️ platform. The company’s lead molecules remain in preclinical development with no published clinical results yet. Their approach enables high-throughput functional screening in cell-based assays but has not advanced to IND or clinical stages as of early 2024.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Protein therapeutics (including antibodies and enzymes)Antibody-based proteinsEnzymes
Industry: Biotech

Drug pipeline

1 asset

LGTX-101

Preclinical

Partnerships

M Ventures (investor/partner)Atomico (investor/partner)Obvious Ventures; no major pharma partnerships publicly announced.

Beyond the preview

Go deeper on LabGenius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LabGenius.

Explore the full profile